GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sutro Biopharma Inc (NAS:STRO) » Definitions » Gross Margin %

Sutro Biopharma (Sutro Biopharma) Gross Margin % : 0.00% (As of Mar. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Sutro Biopharma Gross Margin %?

Gross Margin % is calculated as gross profit divided by its revenue. Sutro Biopharma's Gross Profit for the three months ended in Mar. 2024 was $13.0 Mil. Sutro Biopharma's Revenue for the three months ended in Mar. 2024 was $13.0 Mil. Therefore, Sutro Biopharma's Gross Margin % for the quarter that ended in Mar. 2024 was 0.00%. If there's no value for Cost of Goods Sold, then Gross Margin % is not calculated.


The historical rank and industry rank for Sutro Biopharma's Gross Margin % or its related term are showing as below:


STRO's Gross Margin % is not ranked *
in the Biotechnology industry.
Industry Median: 60.43
* Ranked among companies with meaningful Gross Margin % only.

Sutro Biopharma had a gross margin of N/A% for the quarter that ended in Mar. 2024 => No sustainable competitive advantage

The 5-Year average Growth Rate of Gross Margin for Sutro Biopharma was 0.00% per year.


Sutro Biopharma Gross Margin % Historical Data

The historical data trend for Sutro Biopharma's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sutro Biopharma Gross Margin % Chart

Sutro Biopharma Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Gross Margin %
Get a 7-Day Free Trial - - - - -

Sutro Biopharma Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Gross Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Sutro Biopharma's Gross Margin %

For the Biotechnology subindustry, Sutro Biopharma's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sutro Biopharma's Gross Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sutro Biopharma's Gross Margin % distribution charts can be found below:

* The bar in red indicates where Sutro Biopharma's Gross Margin % falls into.



Sutro Biopharma Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue. (Note that if there's no value for Cost of Goods Sold, then Gross Margin % is not calculated.)

Sutro Biopharma's Gross Margin for the fiscal year that ended in Dec. 2023 is calculated as

Gross Margin % (A: Dec. 2023 )=Gross Profit (A: Dec. 2023 ) / Revenue (A: Dec. 2023 )
=153.7 / 153.731
=(Revenue - Cost of Goods Sold) / Revenue
=(153.731 - 0) / 153.731
=N/A %

Sutro Biopharma's Gross Margin for the quarter that ended in Mar. 2024 is calculated as


Gross Margin % (Q: Mar. 2024 )=Gross Profit (Q: Mar. 2024 ) / Revenue (Q: Mar. 2024 )
=13 / 13.008
=(Revenue - Cost of Goods Sold) / Revenue
=(13.008 - 0) / 13.008
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Sutro Biopharma  (NAS:STRO) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Sutro Biopharma had a gross margin of N/A% for the quarter that ended in Mar. 2024 => No sustainable competitive advantage


Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.


Sutro Biopharma Gross Margin % Related Terms

Thank you for viewing the detailed overview of Sutro Biopharma's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Sutro Biopharma (Sutro Biopharma) Business Description

Traded in Other Exchanges
Address
111 Oyster Point Boulevard, South San Francisco, CA, USA, 94080
Sutro Biopharma Inc is clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers.
Executives
Hans-peter Gerber officer: Chief Scientific Officer C/O SUTRO BIOPHARMA, INC., 111 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Brunilda Shtylla officer: Chief Business Officer C/O SUTRO BIOPHARMA, INC., 111 OYSTER POINT BLVD., SOUTH SAN FRANCISCO CA 94080
Venkatesh Srinivasan officer: Chief Tech Op Officer C/O SUTRO BIOPHARMA, INC., 111 OYSTER POINT BLVD., SOUTH SAN FRANCISCO CA 94080
Anne Elizabeth Borgman officer: Chief Medical Officer 9000 VIRGINIA MANOR ROAD, SUITE 200, BELTSVILLE MD 20705
William J Newell director, officer: CEO & President 887 GREAT NORTHERN WAY, VANCOUVER A1 V5T 4T5
Heidi Hunter director C/O SUTRO BIOPHARMA, INC., 310 UTAH AVE., SUITE 150, SOUTH SAN FRANCISCO CA 94080
Nicki Vasquez officer: Chief Port. Strat & Alnce Ofcr C/O SUTRO BIOPHARMA, INC., 310 UTAH AVE., SUITE 150, SOUTH SAN FRANCISCO CA 94080
Jane Chung officer: Chief Commercial Officer C/O SUTRO BIOPHARMA, INC., 310 UTAH AVE., SUITE 150, SOUTH SAN FRANCISCO CA 94080
Trevor Hallam officer: Chief Science Officer PALATIN TECHNOLOGIES, INC., 4C CEDAR BROOK DRIVE, CRANBURY NJ 08512
Jon Marc Wigginton director 9640 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850
John Gordon Freund director, 10 percent owner 125 UNIVERSITY AVE., C/O SKYLINE VENTURES, PALO ALTO CA 94301
Arturo Md Molina officer: Chief Medical Officer 10990 WILSHIRE BLVD, SUITE 1200, LOS ANGELES CA 90024
Linda A Fitzpatrick officer: Chief People & Comm. Officer NUVELO, INC., 675 ALMANOR AVENUE, SUNNYVALE CA 94085
James P Panek director C/O VAXGEN INC, 1000 MARINA BLVD. #200, BRISBANE CA 94005
Matsui Connie director 3030 CALLAN RD, SAN DIEGO CA 92121

Sutro Biopharma (Sutro Biopharma) Headlines

From GuruFocus

Sutro Biopharma to Participate in the Jefferies Healthcare Conference

By sperokesalga sperokesalga 05-31-2023

Sutro Biopharma to Participate in Upcoming Investor Conferences

By Value_Insider Value_Insider 11-02-2022

Sutro Biopharma Appoints Dr. Anne Borgman as Chief Medical Officer

By sperokesalga sperokesalga 02-28-2023